Hi @kensington,
It's good to see another new contributor. You probably already know from your own research that the Phase 1/2 trial results were pretty impressive and that the ongoing OLE study is amplifying those results. Meaning the chance of MPL failing in the P 2/3 STRIKE trial are pretty low. Eg 58% improvement for those on the higher dose and only for a short time, and 91% less chance of death with P values as low as .0154.
My point being whether you buy more at .195 or .22 or .3 really will not matter if the sp gets to $2.00 or more. Many think it will get much higher.
ALS / MND is an unmet need and early indications are that they will not be the last indications MPL may be used to treat.
So get into it and buy if your intending to be a long term holder. [And it may not be that long]
Cheers
Ann: PharmAust Completes Share Purchase Plan, page-33
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.46M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.0¢ | $55.08K | 282.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 192387 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 122595 | 3 |
View Market Depth
| Last trade - 15.48pm 03/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |